Skip to main content

Advertisement

Table 2 The 5-year cancer-specific survival (CSS) rate of the patients with penile cancer

From: A modified clinicopathological tumor staging system for survival prediction of patients with penile cancer

Variable 5-year CSS rate (%, 95% CI)
Training cohort P value External validation cohort P value
T stage   < 0.001   < 0.001
 ≤ T1a 87.5 (81.0–94.0) 94.6 (90.0–99.1)
 T2 63.0 (51.0–75.0) 75.3 (66.5–84.1)
 T3 56.2 (42.7–69.7) 70.1 (61.7–78.5)
 T4 13.0 (0–33.8) 11.1 (0–31.7)
N stage   < 0.001   < 0.001
 N0 94.3 (90.8–97.8) 90.8 (87.3–94.3)
 N1 68.0 (50.6–85.4) 55.7 (29.2–82.2)
 N2 9.5 (0–21.8) 12.9 (0–29.4)
 N3 0   0
M stage   < 0.001   < 0.001
 M0 69.9 (63.8–76.0) 79.6 (75.1–84.1)
 M1 0 0
Pathological grade   < 0.001   0.002
 G1–2 71.6 (65.5–83.8) 81.4 (76.3–86.5)
 G3 18.7 (0–47.7) 69.8 (60.2–79.4)
Lymphovascular embolization   < 0.001   < 0.001
 Yes 30.8 (15.9–45.7) 50.0 (38.8–61.2)
 No 77.0 (70.9–77.0) 86.5 (82.2–90.8)
Perineural invasion   < 0.001   0.010
 Yes 40.3 (23.6–57.0) 65.7 (52.0–79.4)
 No 73.3 (67.0–79.6) 80.5 (75.8–85.2)
Modified staging system   < 0.001   < 0.001
 ≤ t1b 87.5 (81.0–94.0) 94.6 (90.0–99.1)
 t2 69.2 (59.2–89.2) 82.5 (76.4–88.6)
 t3 33.4 (16.5–50.3) 42.9 (29.2–56.6)
 t4 13.0 (0–33.8) 11.1 (0–31.7)
  1. CI confidence interval
  2. a≤ T1 includes T0, Tis, Ta, and T1
  3. b≤ t1 includes t0, tis, ta, and t1